Indivior (NASDAQ:INDV) Sets New 12-Month High – Here’s What Happened

Indivior PLC (NASDAQ:INDV)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $41.12 and last traded at $41.05, with a volume of 267098 shares. The stock had previously closed at $39.96.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Weiss Ratings lowered shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 16th. Finally, Barclays started coverage on shares of Indivior in a research note on Thursday, June 18th. They issued an “overweight” rating and a $46.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $40.29.

Indivior Stock Performance

The stock has a market cap of $5.04 billion, a PE ratio of 21.26 and a beta of 0.88. The stock has a fifty day simple moving average of $36.49 and a two-hundred day simple moving average of $34.54.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. The company had revenue of $317.00 million for the quarter. On average, equities analysts predict that Indivior PLC will post 4.05 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Ryan Preblick sold 36,000 shares of the firm’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the completion of the sale, the chief financial officer directly owned 284,751 shares of the company’s stock, valued at approximately $10,735,112.70. This trade represents a 11.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.74% of the company’s stock.

Hedge Funds Weigh In On Indivior

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INDV. Caitong International Asset Management Co. Ltd grew its stake in shares of Indivior by 72.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after acquiring an additional 460 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its stake in shares of Indivior by 3.4% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 21,200 shares of the company’s stock worth $761,000 after acquiring an additional 700 shares in the last quarter. Blue Trust Inc. lifted its stake in shares of Indivior by 17.8% in the fourth quarter. Blue Trust Inc. now owns 4,859 shares of the company’s stock worth $176,000 after acquiring an additional 733 shares in the last quarter. Harbor Capital Advisors Inc. boosted its holdings in Indivior by 309.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after purchasing an additional 781 shares during the last quarter. Finally, Salomon & Ludwin LLC purchased a new position in Indivior in the fourth quarter valued at about $30,000. 60.33% of the stock is owned by hedge funds and other institutional investors.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.